Hyundai Bioscience Co. Ltd (048410.KQ) stock: key figures, P/E, revenue and dividend
Information Technology · Technology Hardware, Storage & Peripherals · South Korea · ISIN KR7048410005
Hyundai Bioscience Co. Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 15.05 bn KRW | 3.52 bn KRW |
| Gross profit | 11.87 bn KRW | 243.63 m KRW |
| Operating income | 790.97 m KRW | -18.16 bn KRW |
| EBIT | -4.57 bn KRW | -19.67 bn KRW |
| Net income | -6.93 bn KRW | -22.13 bn KRW |
| Diluted EPS – continuing operations | -87.01 KRW | -230.41 KRW |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
More stocks
- Jiangsu Apon Medical Technology Co Ltd Class A (300753.SZ)
- Xinjiang Chalkis Co Ltd (000972.SZ)
- First Bancorp, Inc /ME/ (FNLC)
- CHEMUNG FINANCIAL CORP (CHMG)
- CITIZENS FINANCIAL SERVICES INC (CZFS)
- Surya Permata Andalan Tbk PT (NATO.JK)
- BlossomHill Therapeutics, Inc. Common Stock (BLSM)
- Avalo Therapeutics, Inc. (AVTX)
- Oxiquim S.A (OXIQUIM.SN)
- Hamilton Beach Brands Holding Co (HBB)
- Infinity Capital Investments S.A. (INFINITY.RO)
- AEM (AEM.AT)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.